Polyradiculoneuropathy clinical trials
The registry lists 41 studies for Polyradiculoneuropathy across more than 10 countries. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-18.
Status
- Completed
- 25
- Status unknown
- 4
- Recruiting
- 3
- Terminated
- 3
- Active, not recruiting
- 2
- Not yet recruiting
- 2
Phase
- Phase 3
- 13
- Phase 2
- 8
- Phase 4
- 2
- Early Phase 1
- 2
- Phase 1
- 2
Where
- France
- 17
- Italy
- 12
- United States
- 12
- United Kingdom
- 11
- Spain
- 10
- Denmark
- 8
Who runs them
University of Aarhus (4) · Istituto Clinico Humanitas (3) · National Center for Research Resources (NCRR) (3) · CSL Behring (2) · Baxalta now part of Shire (2) · Hadassah Medical Organization (2) · Fondation Hôpital Saint-Joseph (2) · Laboratoire français de Fractionnement et de Biotechnologies (2)
Studies
Recruiting first, then most recently updated. Showing 41 of 41 — search for more.
- Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune DiseasesRecruitingNCT07022197Phase 1/21 country
- Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.Not yet recruitingNCT06485232Early Phase 11 country
- Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous SystemRecruitingNCT04561557Early Phase 11 country
- Genetic Architecture of Chronic Inflammatory Demyelinating PolyradiculoneuropathyRecruitingNCT06325878Not applicable1 country
- Processing Integration in Neurological Patients Using fMRINot yet recruitingNCT02722070
- Upper Limb Robot-Assisted Therapy in Patients With Guillain-Barré SyndromeActive, not recruitingNCT06620198Phase 41 country
- Role of High Frequency Ultrasound in Demyelinating PolyneuropathiesCompletedNCT049786231 country
- Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDPCompletedNCT02955355Phase 318 countries
- A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347TerminatedNCT03275740Phase 15 countries
- Rituximab in Chronic Inflammatory Demyelinating PolyradiculoneuropathyCompletedNCT06325943Phase 31 country
- A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating PolyradiculoneuropathyCompletedNCT03861481Phase 28 countries
- A Proof of Concept Study With Rituximab in Patients With CIDP Not Responding to Conventional Immune TherapyActive, not recruitingNCT05877040Phase 21 country
- A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)CompletedNCT02549170Phase 322 countries
- A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)CompletedNCT053633581 country
- Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating PolyradiculoneuropathyCompletedNCT026297961 country
- A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating PolyradiculoneuropathyCompletedNCT04051944Phase 28 countries
- Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous ImmunoglobulinCompletedNCT02892890Not applicable1 country
- InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating PolyradiculoneuropathyWithdrawnNCT04529291Not applicable
- Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuropathy With Antibody A MAGCompletedNCT03008733Not applicable1 country
- Study of Electrical Prognostic Factors of Response to Intravenous Immunoglobulin Treatment in Chronic Inflammatory Demyelinating PolyradiculoneuropathyCompletedNCT039678991 country
- The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 AutoantibodiesCompletedNCT03864185Phase 21 country
- Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302TerminatedNCT02317562Phase 36 countries
- Efficacy and Safety Study of I10E in Treatment of Patients With CIDPCompletedNCT02293460Phase 36 countries
- Biomarkers in PolyradiculoneuropathiesStatus unknownNCT042497521 country
- Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CompletedNCT02027701Phase 311 countries
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)CompletedNCT01545076Phase 316 countries
- Transcriptome Analysis of the Peripheral Blood in CIDPStatus unknownNCT02404298Not applicable1 country
- Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC)CompletedNCT034609511 country
- Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.CompletedNCT01625182Phase 315 countries
- Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)WithdrawnNCT01757574Phase 41 country
- Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDPTerminatedNCT01225276Phase 2/3
- MRI in Diagnosing and Monitoring CIDPCompletedNCT020177691 country
- sCD163 & CD19 as Candidate Biomarkers in CIDP and MMNStatus unknownNCT022717241 country
- Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CompletedNCT00220740Phase 310 countries
- Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)CompletedNCT01017159Phase 21 country
- Perception and Multisensory Integration in Neurological Patients Using fMRIStatus unknownNCT01469858Not applicable1 country
- Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)CompletedNCT00099489Phase 24 countries
- Study of CIDP Patients During IVIG TreatmentCompletedNCT003052661 country
- Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating PolyneuropathyCompletedNCT00004772Phase 3
- Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating PolyneuropathyCompletedNCT00004939Phase 3
- Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating NeuropathyCompletedNCT00004286Phase 3